您好,欢迎来到化工原料网! [登录] [免费注册]
化工原料网
位置:首页 > 产品库 > FG-4592(ASP1517)
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
FG-4592(ASP1517)
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
FG-4592(ASP1517)图片
包装与价格:
包装价格(元)
10mM (in 1mL DMSO)电议
10mg电议
50mg电议
100mg电议
200mg电议
500mg电议

产品介绍
FG-4592 (ASP1517) 是一种口服活性缺氧诱导因子 (HIF) 脯氨酰羟化酶 (PHD) 抑制剂 (HIF-PHI),通过增加内源性红细胞生成素、改善铁调节和减少铁调素来促进红细胞生成。

Cell lines

Primary culture of hippocampal neurons

Preparation Method

Hippocampal primary neurons were treated with 50 μM and 10 μM FG-4592 for 72 h, starting from the second day in vitro. Microtubule-associated protein 2 (MAP2) staining and Western blotting were performed after cell collection.

Reaction Conditions

50 μM and 10 μM, 72h

Applications

FG-4592 promoted dendritic growth of primary hippocampal neurons in vitro.

Animal models

Wild-type C57BL/6 mice (10–12 weeks old, weighing 25–28 g)

Preparation Method

The FG-4592 was dissolved in DMSO at the concentration of 50 mg/ml and further diluted in PBS to 1 mg/ml. The mice were pretreated with FG-4592 for 48 h in FG-4592+Doxorubicin group at a dose of 10 mg/kg/day before Doxorubicin treatment.

Dosage form

10 mg/kg/day;intraperitoneal injection

Applications

FG-4592 rescued the reduction of LVEF and LVFS induced by Doxorubicin. FG-4592 obviously attenuated Doxorubicin-induced acute cardiac dysfunction and cardiomyocyte injury.

文献引用
产品描述

FG-4592, as an oral bioavailable hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor, can promote coordinated erythropoiesis through HIF-mediated transcription. FG-4592 was well tolerated and corrected anemia in incident HD and PD patients.[1]

In vitro, treated with 10 μM or 50 μM FG-4592 in Primary Hippocampal Neurons, FG-4592 dose-dependently increased protein levels of HIF-1, and its target genes EPO and VEGF, as well as BDNF and PSD95.[2]In vitro experiment it exhibited that treatment with 2, 10, and 20 μM FG-4592 dose-dependently reduced ROS generation and inflammation in LPS-stimulated BV-2 cells, a mouse microglia cell line, by inhibiting HIF-1α/NF-κB pathway.[3]In HK-2 cells, treatment with 15 μM FG-4592 the injury induced by hypoxia remarkably ameliorated.[5]

In vivo experiment it shown that treatment with 20 mg/kg/day FG-4592 intraperitoneally in Rat significantly affected body weight gain. In vivo efficacy it indicated that the high dose FG-4592 (20 mg/kg/day) could effectively reverse CUMS-induced depression-like behaviors.[2]In vivo, mice were treated with 10 mg/kg FG-4592 intraperitoneally exhibited an improved renal function, compared with those without FG-4592 by biochemical and histological parameters.[4]In C57BL/6 mice, treatment with 25.0 mg/kg FG-4592 intraperitoneally 24 and 2 h before irradiation, and then followed by total body irradiation of 8.5 Gy or local abdominal irradiation of 25.0 Gy could dramatically improve the survival rate of mice after IR.[6]

References:
[1]Besarab A, Chernyavskaya E, Motylev I, Shutov E, Kumbar LM, Gurevich K, Chan DT, Leong R, et al. Roxadustat (FG-4592): Correction of Anemia in Incident Dialysis Patients. J Am Soc Nephrol. 2016 Apr;27(4):1225-33.
[2]Li G, et al. FG-4592 Improves Depressive-Like Behaviors through HIF-1-Mediated Neurogenesis and Synapse Plasticity in Rats. Neurotherapeutics. 2020 Apr;17(2):664-675.
[3]Yang DG, et al. Roxadustat alleviates nitroglycerin-induced migraine in mice by regulating HIF-1α/NF-κB/inflammation pathway. Acta Pharmacol Sin. 2022 Aug 10.
[4]Li X, et al. Pretreatment with Roxadustat (FG-4592) Attenuates Folic Acid-Induced Kidney Injury through Antiferroptosis via Akt/GSK-3β/Nrf2 Pathway. Oxid Med Cell Longev. 2020 Jan 20;2020:6286984.
[5]Miao AF, et al. Hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) protects against renal ischemia/reperfusion injury by inhibiting inflammation. Ren Fail. 2021 Dec;43(1):803-810.
[6]Feng Z, et al. FG-4592 protects the intestine from irradiation-induced injury by targeting the TLR4 signaling pathway. Stem Cell Res Ther. 2022 Jun 21;13(1):271.